Biogen BIIB
NASDAQ BIIB
$219.88 -2.94 (-1.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Biogen (BIIB) Gains from Equity Investments (2019)

Updated

Biogen's Gains from Equity Investments was $142.9 million in Q4 2019.

Analysis

Biogen (BIIB) Gains from Equity Investments (2019) Analysis & Trends

For FY2019, Gains from Equity Investments at Biogen came in at $79.4 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Biogen 32.49 Bn 19.14 Bn 1.96 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 142.90 Mn
API Access

Biogen Gains from Equity Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=BIIB&period=max&api_key=YOUR_API_KEY